Platelet procoagulant

Solution for haemorrhage induces by anticoagulant and anti platelet therapies. Thrombotargets Biotech Corporation has developed a procoagulant drug call TT-103MH to stop bleeding topically. 

The novel and most revolutionary hemostatic agents. Thrombotargets has developed the TT-103MH, the human recombinant antibleeding protein that has been designed to treat all kind of bleeding disorders

Our pipeline is comprised of innovative drug candidates in the fields of Hemostasis and Thrombosis. Some of these compounds, as our recently Orphan Drug Designated TT-103MH topical antihemorrhagic recombinant protein, are available for licensing out. We also have new anticoagulants, antifibrinolytics, antiplatelet agents, and are working on innovative gene therapies for the treatment of coagulation disorders (Hemophilia, von Willebrand disease, etc).

Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.